ReviewDiabetologia2022
A novel diabetes typology: towards precision diabetology from pathogenesis to treatment.
Review in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Endocrinology, diabetes & metabolism · 2026Pooled it
- EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Obesity facts · 2024Guideline
- Ethnic differences between Asians and non-Asians in clustering-based phenotype classification of adult-onset diabetes mellitus: A systematic narrative review.Primary care diabetes · 2022Pooled it
- How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.Diabetologia · 2023Trial
- Association of Type 2 Diabetes Subgroups With Cognitive Status Without Modification From Lifestyle Intervention.The Journal of clinical endocrinology and metabolism · 2023Trial
- Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial.Frontiers in endocrinology · 2022Trial
- Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches.Diabetologia · 2026Review
- Refining the Genetic Contribution to Type 2 Diabetes Subtypes.Diabetes, obesity & metabolism · 2026Article
- Differential associations of dietary patterns with estimated 10-year cardiovascular risk in diabetes subtypes.Scientific reports · 2026Observational
- Subtypes of newly diagnosed type 2 diabetes and risk of complications: analysis of electronic health records in the USA.Diabetologia · 2026Article
- GLP-1 agonists and the gut microbiome: A bidirectional relationship.British journal of clinical pharmacology · 2026Review
- Review
- Validation of a Diabetes Subtype Classification Model Using Data from U.S. Adults Before and After the COVID-19 Pandemic.Metabolites · 2026Article
- Type 2 Diabetes in Morocco: Toward a Precision Diabetology, from Pathogenesis to Treatment.Annals of African medicine · 2026Article
- Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans.Hormones (Athens, Greece) · 2026Review
- Precision phenotyping of type 2 diabetes in chinese populations using a variational autoencoder-informed tree model.Nature communications · 2026Article
- Divergent Trajectories of the Burden of MASLD Attributable to High Fasting Plasma Glucose in China and Globally: A GBD Study 1990-2021 and Projections to 2046.Gastroenterology research and practice · 2026Article
- Quantitative analysis of human adult pancreatic histology reveals separate fatty and fibrotic phenotypes in type 2 diabetes.Diabetologia · 2025Article
- Integrative proteomic analysis provides novel therapeutic insights for etiological subtypes of diabetes.Diabetes, obesity & metabolism · 2025Article
- Diabetes prevention and treatment: a global perspective.Diabetologia · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current classification of diabetes, based on hyperglycaemia, islet-directed antibodies and some insufficiently defined clinical features, does not reflect differences in aetiological mechanisms and in the clinical course of people with diabetes. This review discusses evidence from recent studies addressing the complexity of diabetes by proposing novel subgroups (subtypes) of diabetes. The most widely replicated and validated approach identified, in addition to severe autoimmune diabetes, four subgroups designated severe insulin-deficient diabetes, severe insulin-resistant diabetes, mild obesity-related diabetes and mild age-related diabetes subgroups. These subgroups display distinct patterns of clinical features, disease progression and onset of comorbidities and complications, with severe insulin-resistant diabetes showing the highest risk for cardiovascular, kidney and fatty liver diseases. While it has been suggested that people in these subgroups would benefit from stratified treatments, RCTs are required to assess the clinical utility of any reclassification effort. Several methodological and practical issues also need further study: the statistical approach used to define subgroups and derive recommendations for diabetes care; the stability of subgroups over time; the optimal dataset (e.g. phenotypic vs genotypic) for reclassification; the transethnic generalisability of findings; and the applicability in clinical routine care. Despite these open questions, the concept of a new classification of diabetes has already allowed researchers to gain more insight into the colourful picture of diabetes and has stimulated progress in this field so that precision diabetology may become reality in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.